Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.78 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13343956 | 1.00 | BLM (0.78) | BLMLTA4HGABRR1CYP1A2ACE2 | |
| SCHEMBL5878899 | 0.97 | BLM (0.75) | BLMLTA4HGABRR1CYP1A2ACE2 | |
| SCHEMBL5878947 | 0.97 | BLM (0.75) | BLMLTA4HGABRR1CYP1A2ACE2 | |
| SCHEMBL6936832 | 0.97 | BLM (0.75) | BLMLTA4HGABRR1CYP1A2ACE2 | |
| SCHEMBL5879045 | 0.97 | BLM (0.75) | BLMLTA4HGABRR1CYP1A2ACE2 | |
| SCHEMBL5879031 | 0.97 | BLM (0.75) | BLMLTA4HGABRR1CYP1A2ACE2 | |
| SCHEMBL8042148 | 0.97 | BLM (0.75) | BLMLTA4HGABRR1CYP1A2ACE2 | |
| SCHEMBL5878707 | 0.97 | BLM (0.75) | BLMLTA4HGABRR1CYP1A2ACE2 | |
| SCHEMBL15270947 | 0.97 | BLM (0.75) | BLMLTA4HGABRR1CYP1A2ACE2 | |
| SCHEMBL20377187 | 0.97 | BLM (0.75) | BLMLTA4HGABRR1CYP1A2ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4641061-A1 | OIL-WELL METAL PIPE | NIPPON STEEL CORPORATION (JP) | 2025-10-29 | — | — | EP | claimed |
| WO-2024135464-A1 | OIL-WELL METAL PIPE | 日本製鉄株式会社 | 2024-06-27 | — | — | WO | claimed |
| EP-4641061-A1 | OIL-WELL METAL PIPE | NIPPON STEEL CORPORATION (JP) | 2025-10-29 | — | — | EP | disclosed |
| EP-3839028-B1 | CLEANING PRODUCT | PROCTER & GAMBLE (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240408180-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4412587-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | President And Fellows Of Harvard College (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118382429-A | Ionic liquids for drug delivery | 哈佛大学校长及研究员协会 | 2024-07-23 | — | — | CN | disclosed |
| WO-2024135464-A1 | OIL-WELL METAL PIPE | 日本製鉄株式会社 | 2024-06-27 | — | — | WO | disclosed |
| EP-4386075-A2 | CLEANING PRODUCT | The Procter & Gamble Company (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11834629-B2 | Cleaning product | THE PROCTER & GAMBLE COMPANY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834627-B2 | Cleaning product | THE PROCTER & GAMBLE COMPANY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20170296986-A1 | UNIVERSAL SCALABLE AND COST-EFFECTIVE SURFACE MODIFICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-10-19 | — | — | US | disclosed |
| US-9662617-B2 | Universal scalable and cost-effective surface modifications | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-30 | — | — | US | disclosed |
| EP-3121184-A2 | BENZENE-BASED DIPHOSPHINE LIGANDS FOR ALKOXYCARBONYLATION | Evonik Degussa GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3121185-A2 | PHOSPHIN LIGAND AND PALLADIUM CATALYST BASED ON SAME FOR ALKOXYCARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | Evonik Degussa GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3121180-A2 | BUTYL-BRIDGED DIPHOSPHINE LIGANDS FOR ALKOXYCARBONYLATION | Evonik Degussa GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3121179-A2 | FERROCENE-BASED COMPOUNDS AND PALLADIUM CATALYSTS BASED ON SAME FOR THE ALKOXYCARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | Evonik Degussa GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3121186-A2 | FERROCENE-BASED COMPOUNDS AND PALLADIUM CATALYSTS BASED ON SAME FOR THE ALKOXYCARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | Evonik Degussa GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| US-20160001236-A1 | Universal Scalable and Cost-Effective Surface Modifications | NATIONAL SCIENCE FOUNDATION | 2016-01-07 | — | — | US | disclosed |
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | THE PROCTER & GAMBLE COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160001236-A1 | Universal Scalable and Cost-Effective Surface Modifications | EPCAM, CD59, SIGLEC9 | BLM 1608/4885LTA4H 3686/4885GABRR1 3254/4885 |
| US-20170296986-A1 | UNIVERSAL SCALABLE AND COST-EFFECTIVE SURFACE MODIFICATIONS | EPCAM, CD59, SIGLEC9 | BLM 1608/4885LTA4H 3686/4885GABRR1 3254/4885 |
| US-20240408180-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | SLCO4C1, SLC47A1, ABCB11 | BLM 907/4885LTA4H 1721/4885GABRR1 2691/4885 |
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | TRPA1, TAS2R40, TAS2R30 | BLM 2059/4885LTA4H 1306/4885GABRR1 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.